1[1]Danzi GB,Capuano C,Sesana M,et al.Variability in ex-tent of platelet function inhibition after administration of optimal dose of glycoprotein Ⅱ b/Ⅲ a receptor blockers in patients undergoing a high-risk percutaneous coronary in-tervention[J].Am J Cardiol,2006,97(4):489-493.
2[2]Servoss SJ,WanY,Snapinn SM,et al.Tirofiban therapy for patient with acute coronary syndrome and prior coro-nary artery bypass grafting in the PRISM-PLUS trial[J].Am J Cardiol,2004,93(7):843-847.
3[3]Valgimili M,Percoco G,Bargieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complication during high-risk coronary angioplasty:the ADVANCE Trial[J].J Am Coll Cardiol,2004,44(1):14-19.
4[4]van't Hof AW,Ernst N,de Boer MJ,et al.Facilitation of primary coronary angioplasty by early start of a glyco-protein Ⅱ b/Ⅲ a inhibitor:results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial[J].Eur Hear J,2004,25(10):837-846.
5[5]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Com-parison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction[J].Am J Car-diol,2004,93(3):280-287.
6[6]Cutlip DE,Riceiardi M J,Ling FS,et al.Effect of tirofi-ban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myo-cardial infarction[J].Am J Cardiol,2003,92 (8):977-980.
7[7]Steen H,Lehrke S,Wiegand UK,et al.Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percuta-neous coronary intervention for ST elevation myocardial irfarc-tion[J].Am Heart J,2005,149(3):564.
8[8]Lee DP,Herity NA,Hiatt BL,et al.Adjunctive platelet glycoprotein Ⅱ b/Ⅲa receptor inhibition with tirofiban be-fore primary angioplasty improves angiographic outcomes:results of the TIrofiban Given in the Emergency Room be-fore Primary Angioplasty (TIGER-PA) pilot trial[J].Cir-culation,2003,107(11):1497-1501.
9[9]Bolognese L,Falsini G,Liistro F,et al.Randomized comparison of upstream tirofiban versus downstream high Bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions:the EV-EREST trial[J].J Am Coil Cardiol,2006,47(3):522-528.
10[10]Karvouni E,Kattitsis DG,loannidis JP.Intravenous gly-coprotein Ⅱb/Ⅲ a receptor antagonists reduce mortality after percutaneous coronary interventions[J].J Am Coll Cardiol,2003,41(1):26-32.
二级参考文献22
1Brener SJ, Barr LA, Burehenal JE, et al. Randomized, placebocontrolled trial of platelet glycoprotein Ⅱb/Ⅲa blockade with primary PTCA Organization and Randomized Trial (RAPPORT). Circulation, 1998, 98 (8) : 734-741.
2Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱb/Ⅲa inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344 ( 25 ) : 1895-1903.
3Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346(13): 957-966.
4Neuman FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein Ⅱb/Ⅲa receptor blockade with abciximab on clinical and angiographic restenosis rate after of coronary stents following acute myocardial infarction. J Am Coll Cardial, 2000,35(4) :915-921.
5Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 1998,338(21) : 1498-1505.
6Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable sign and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 1998,338 (21) : 1488- 1497.
7The RESTORE Investigators. Effects ,of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96(5) : 1445-1453.
8Uyarel H, Uzunlar B, Unal Dayi S, et al. Effect of Tirofiban Therapy on ST Segment Resolution and Clinical Outcomes in Patients with ST Segment Elevated Acute Myocardial Infarction Undergoing Primary Angioplasty. Cardiology,2006,105 (3) : 168- 175.
9Martinez-Rios MA, Rosas M, Gonzalez H, et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol,2004, 93 (3) :280-287.
10Yip HK, Wu CJ, Chang HW, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes. Chest, 2003,124(3 ) :962-968.
6Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：344
